Kura Oncology Inc Financials

KURA

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

Financial Health Signals

Financial Profile 75/100

Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Kura Oncology Inc has an operating margin of -358.6%, meaning the company retains $-359 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses.

Leverage

100

Kura Oncology Inc carries a low D/E ratio of 0.02, meaning only $0.02 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 9.46, Kura Oncology Inc holds $9.46 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

100

Kura Oncology Inc converts 248.4% of revenue into free cash flow ($133.8M). This strong cash generation earns a score of 100/100.

Piotroski F-Score Neutral

4/9

Kura Oncology Inc passes 4 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Mixed

-0.77x

For every $1 of reported earnings, Kura Oncology Inc generates $-0.77 in operating cash flow ($134.3M OCF vs -$174.0M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Interest Coverage At Risk

-119.3x

Kura Oncology Inc earns $-119.3 in operating income for every $1 of interest expense (-$193.2M vs $1.6M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

This page shows Kura Oncology Inc (KURA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 18 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Export CSV

Key Financial Metrics

Revenue

$53.9M

Kura Oncology Inc generated $53.9M in revenue in fiscal year 2024.

EBITDA

-$192.3M

YoY-16.6%

Kura Oncology Inc's EBITDA was -$192.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 16.6% from the prior year.

Free Cash Flow

$133.8M

YoY+207.1%

Kura Oncology Inc generated $133.8M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 207.1% from the prior year.

Net Income

-$174.0M

YoY-14.0%

Kura Oncology Inc reported -$174.0M in net income in fiscal year 2024. This represents a decrease of 14.0% from the prior year.

EPS (Diluted)

$-2.02

YoY+2.9%

Kura Oncology Inc earned $-2.02 per diluted share (EPS) in fiscal year 2024. This represents an increase of 2.9% from the prior year.

Cash & Debt

$224.5M

YoY+501.5%

5Y CAGR+53.7%

10Y CAGR+69.8%

Kura Oncology Inc held $224.5M in cash against $6.9M in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

78M

YoY+5.2%

5Y CAGR+11.5%

Kura Oncology Inc had 78M shares outstanding in fiscal year 2024. This represents an increase of 5.2% from the prior year.

Gross Margin

N/A

Operating Margin

-358.6%

Kura Oncology Inc's operating margin was -358.6% in fiscal year 2024, reflecting core business profitability.

Net Margin

-322.9%

Kura Oncology Inc's net profit margin was -322.9% in fiscal year 2024, showing the share of revenue converted to profit.

Return on Equity

N/A

R&D Spending

$170.0M

YoY+47.5%

5Y CAGR+28.9%

Kura Oncology Inc invested $170.0M in research and development in fiscal year 2024. This represents an increase of 47.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$472K

YoY+181.0%

Kura Oncology Inc invested $472K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 181.0% from the prior year.

KURA Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$53.9M	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$170.0M+47.5%	$115.2M+24.2%	$92.8M+9.6%	$84.7M+40.3%	$60.4M+26.3%	$47.8M
SG&A Expenses	$77.1M+52.5%	$50.6M+7.5%	$47.1M+1.1%	$46.5M+47.7%	$31.5M+60.3%	$19.7M
Operating Income	-$193.2M-16.5%	-$165.8M-18.5%	-$139.9M	N/A	N/A	N/A
Interest Expense	$1.6M+4.5%	$1.5M+576.4%	$229K-44.7%	$414K-28.4%	$578K-0.3%	$580K
Income Tax	$2.0M	$0	$0	$0	$0	$0
Net Income	-$174.0M-14.0%	-$152.6M-12.4%	-$135.8M-4.1%	-$130.5M-45.6%	-$89.6M-41.9%	-$63.1M
EPS (Diluted)	$-2.02+2.9%	$-2.08-2.5%	$-2.03-3.0%	$-1.97-16.6%	$-1.69	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22
Revenue	$20.8M+35.7%	$15.3M+8.4%	$14.1M	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$67.9M+8.2%	$62.8M+12.2%	$56.0M+34.2%	$41.7M	N/A	$29.3M	N/A	$25.0M
SG&A Expenses	$32.8M+30.5%	$25.2M+10.2%	$22.8M+25.6%	$18.2M	N/A	$13.1M	N/A	$11.6M
Operating Income	-$80.0M-10.1%	-$72.7M-12.3%	-$64.7M-8.0%	-$59.9M	N/A	N/A	N/A	N/A
Interest Expense	$393K+0.5%	$391K+2.4%	$382K-7.3%	$412K	N/A	$404K	N/A	N/A
Income Tax	N/A	N/A	$226K	N/A	N/A	N/A	N/A	N/A
Net Income	-$74.1M-12.1%	-$66.1M-15.1%	-$57.4M-5.6%	-$54.4M	N/A	-$38.6M	N/A	-$35.5M
EPS (Diluted)	$-0.85-13.3%	$-0.75-13.6%	$-0.66-4.8%	$-0.63	N/A	$-0.50	N/A	$-0.53

KURA Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$760.2M+69.3%	$448.9M-1.6%	$456.3M-14.6%	$534.1M-17.5%	$647.2M+167.5%	$242.0M
Current Assets	$744.8M+72.2%	$432.5M-3.1%	$446.4M-14.5%	$522.3M-18.0%	$637.3M+166.0%	$239.6M
Cash & Equivalents	$224.5M+501.5%	$37.3M-28.0%	$51.8M-42.9%	$90.7M-72.1%	$325.5M+1145.4%	$26.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$2.1M	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$346.5M+570.7%	$51.7M+43.4%	$36.0M+31.3%	$27.4M-24.4%	$36.3M+56.6%	$23.2M
Current Liabilities	$78.7M+123.2%	$35.3M+46.6%	$24.1M+7.1%	$22.5M-13.7%	$26.0M+67.2%	$15.6M
Long-Term Debt	$6.9M-25.9%	$9.3M+1.9%	$9.2M	N/A	$4.3M-41.4%	$7.3M
Total Equity	$413.6M+4.1%	$397.3M-5.5%	$420.3M-17.0%	$506.6M-17.1%	$610.9M+179.2%	$218.8M
Retained Earnings	-$895.4M-24.1%	-$721.4M-26.8%	-$568.8M-31.4%	-$433.0M-43.1%	-$302.5M-42.1%	-$212.9M

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22
Total Assets	$649.4M-4.8%	$682.4M-8.2%	$743.8M-2.2%	$760.2M+69.3%	$448.9M-5.2%	$473.8M+3.8%	$456.3M+1.9%	$448.0M
Current Assets	$620.7M-6.0%	$660.1M-8.9%	$724.2M-2.8%	$744.8M+72.2%	$432.5M-6.0%	$459.9M+3.0%	$446.4M+2.3%	$436.4M
Cash & Equivalents	$95.3M+16.3%	$81.9M+59.8%	$51.3M-77.2%	$224.5M+501.5%	$37.3M+29.8%	$28.7M-44.5%	$51.8M-43.0%	$90.9M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$35.9M+685.7%	$4.6M-90.6%	$48.7M+2266.3%	$2.1M	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$406.8M+7.9%	$376.9M-0.6%	$379.4M+9.5%	$346.5M+570.7%	$51.7M+17.9%	$43.8M+21.7%	$36.0M+27.0%	$28.4M
Current Liabilities	$121.3M+13.2%	$107.2M+19.4%	$89.8M+14.0%	$78.7M+123.2%	$35.3M+28.1%	$27.5M+14.4%	$24.1M-2.8%	$24.7M
Long-Term Debt	$5.3M-18.0%	$6.5M-14.9%	$7.7M+10.6%	$6.9M-25.9%	$9.3M+0.5%	$9.3M+1.4%	$9.2M	N/A
Total Equity	$242.5M-20.6%	$305.5M-16.2%	$364.4M-11.9%	$413.6M+4.1%	$397.3M-7.6%	$429.9M+2.3%	$420.3M+0.2%	$419.6M
Retained Earnings	-$1.1B-7.3%	-$1.0B-6.9%	-$952.9M-6.4%	-$895.4M-24.1%	-$721.4M-6.3%	-$678.7M-19.3%	-$568.8M-6.2%	-$535.7M

KURA Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	$134.3M+207.6%	-$124.8M-13.4%	-$110.1M-5.3%	-$104.6M-49.7%	-$69.8M-27.5%	-$54.8M
Capital Expenditures	$472K+181.0%	$168K-73.2%	$626K-45.4%	$1.1M-47.2%	$2.2M	N/A
Free Cash Flow	$133.8M+207.1%	-$125.0M-12.9%	-$110.7M-4.7%	-$105.7M-46.8%	-$72.0M	N/A
Investing Cash Flow	-$101.6M-753.0%	$15.6M-52.3%	$32.6M+125.7%	-$126.8M-26.9%	-$99.9M-115.7%	-$46.3M
Financing Cash Flow	$154.4M+62.9%	$94.8M+145.8%	$38.6M+1222.7%	-$3.4M-100.7%	$469.3M+322.4%	$111.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22
Operating Cash Flow	-$80.6M-180.2%	-$28.8M+60.0%	-$71.9M-126.7%	$269.1M+884.5%	-$34.3M-18.2%	-$29.0M-9.4%	-$26.5M-26.3%	-$21.0M
Capital Expenditures	$2.6M+76.1%	$1.5M+399.3%	$292K-21.5%	$372K+2225.0%	$16K-20.0%	$20K+66.7%	$12K-96.9%	$381K
Free Cash Flow	-$83.2M-175.2%	-$30.2M+58.1%	-$72.2M-126.9%	$268.8M+883.0%	-$34.3M-18.2%	-$29.0M-9.4%	-$26.5M-24.1%	-$21.4M
Investing Cash Flow	$94.0M+59.4%	$58.9M+158.1%	-$101.4M-6.8%	-$95.0M-325.0%	$42.2M+393.0%	$8.6M+118.1%	-$47.3M-165.9%	$71.8M
Financing Cash Flow	$0-100.0%	$515K+260.1%	$143K-82.3%	$806K+16.6%	$691K+722.6%	$84K-99.8%	$34.7M+3844.7%	$880K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

KURA Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-358.6%	N/A	N/A	N/A	N/A	N/A
Net Margin	-322.9%	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-22.9%+11.1pp	-34.0%-4.2pp	-29.8%-5.3pp	-24.4%-10.6pp	-13.9%+12.2pp	-26.1%
Current Ratio	9.46-2.8	12.26-6.3	18.56-4.7	23.26-1.2	24.49+9.1	15.39
Debt-to-Equity	0.020.0	0.020.0	0.02-0.0	0.05+0.0	0.01-0.0	0.03
FCF Margin	248.4%	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-385.5%+89.8pp	-475.3%-16.7pp	-458.6%	N/A	N/A	N/A	N/A	N/A
Net Margin	-357.2%+75.3pp	-432.5%-25.4pp	-407.1%	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-11.4%-1.7pp	-9.7%-2.0pp	-7.7%+3.6pp	-11.4%	N/A	-8.2%	N/A	-7.9%
Current Ratio	5.12-1.0	6.16-1.9	8.07-1.4	9.46-2.8	12.26-4.4	16.71-1.8	18.56+0.9	17.64
Debt-to-Equity	0.020.0	0.020.0	0.020.0	0.020.0	0.020.0	0.020.0	0.02-0.0	0.07
FCF Margin	-400.9%-203.2pp	-197.8%+314.1pp	-511.9%	N/A	N/A	N/A	N/A	N/A

Similar Companies

Arrivent Biopharma Inc AVBP

$927.2M

Tango Therapeutics Inc TNGX

$1.7B

Day One Biopharmaceuticals, Inc. DAWN

$1.2B

Sana Biotechnology, Inc. SANA

$1.0B

Geron Corp GERN

$1.1B

Frequently Asked Questions

What is Kura Oncology Inc's annual revenue?

Kura Oncology Inc (KURA) reported $53.9M in total revenue for fiscal year 2024. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Kura Oncology Inc profitable?

No, Kura Oncology Inc (KURA) reported a net income of -$174.0M in fiscal year 2024, with a net profit margin of -322.9%.

What is Kura Oncology Inc's earnings per share (EPS)?

Kura Oncology Inc (KURA) reported diluted earnings per share of $-2.02 for fiscal year 2024. This represents a 2.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Kura Oncology Inc's EBITDA?

Kura Oncology Inc (KURA) had EBITDA of -$192.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Kura Oncology Inc have?

As of fiscal year 2024, Kura Oncology Inc (KURA) had $224.5M in cash and equivalents against $6.9M in long-term debt.

What is Kura Oncology Inc's operating margin?

Kura Oncology Inc (KURA) had an operating margin of -358.6% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Kura Oncology Inc's net profit margin?

Kura Oncology Inc (KURA) had a net profit margin of -322.9% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Kura Oncology Inc's free cash flow?

Kura Oncology Inc (KURA) generated $133.8M in free cash flow during fiscal year 2024. This represents a 207.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Kura Oncology Inc's operating cash flow?

Kura Oncology Inc (KURA) generated $134.3M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Kura Oncology Inc's total assets?

Kura Oncology Inc (KURA) had $760.2M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Kura Oncology Inc's capital expenditures?

Kura Oncology Inc (KURA) invested $472K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Kura Oncology Inc spend on research and development?

Kura Oncology Inc (KURA) invested $170.0M in research and development during fiscal year 2024.

How many shares does Kura Oncology Inc have outstanding?

Kura Oncology Inc (KURA) had 78M shares outstanding as of fiscal year 2024.

What is Kura Oncology Inc's current ratio?

Kura Oncology Inc (KURA) had a current ratio of 9.46 as of fiscal year 2024, which is generally considered healthy.

What is Kura Oncology Inc's debt-to-equity ratio?

Kura Oncology Inc (KURA) had a debt-to-equity ratio of 0.02 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Kura Oncology Inc's return on assets (ROA)?

Kura Oncology Inc (KURA) had a return on assets of -22.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Kura Oncology Inc's Piotroski F-Score?

Kura Oncology Inc (KURA) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Kura Oncology Inc's earnings high quality?

Kura Oncology Inc (KURA) has an earnings quality ratio of -0.77x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Kura Oncology Inc cover its interest payments?

Kura Oncology Inc (KURA) has an interest coverage ratio of -119.3x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Kura Oncology Inc?

Kura Oncology Inc (KURA) scores 75 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.